Core Insights - Bio-Techne exceeded analysts' expectations for second-quarter revenue and profit, driven by strong demand for its products utilized in drug development [1] Company Performance - The company reported better-than-expected financial results for the second quarter, indicating robust operational performance [1] Market Demand - There is a significant demand for Bio-Techne's products in the drug development sector, which has positively impacted its financial outcomes [1]

Revenue and Sales Performance - Second quarter revenue was $295.9 million, with reported and organic growth flat compared to the prior year[7]. - The Protein Sciences segment reported net sales of $215.1 million, a 2% increase from $211.6 million in the same quarter last year[12]. - The Diagnostics and Spatial Biology segment's net sales were $81.2 million, a decrease of 4% from $84.1 million year-over-year[13]. - Total consolidated net sales for the quarter were $295,877 thousand, slightly down from $297,031 thousand in the previous year, indicating a decrease of 0.4%[27]. - The Protein Sciences segment revenue for the quarter was $215,084 thousand, a slight increase from $211,551 thousand in the previous year, showing a growth of 1.2%[34]. - The Diagnostics and Spatial Biology segment revenue for the quarter was $81,180 thousand, down from $84,135 thousand in the same quarter of 2024, representing a decline of 3.5%[34]. Earnings and Profitability - GAAP earnings per share (EPS) increased to $0.24 from $0.22 year-over-year, while adjusted EPS rose to $0.46 from $0.42[9][10]. - Adjusted operating margin improved to 31.1%, an increase of 100 basis points compared to the prior year period[7]. - GAAP operating income increased 15% to $54.5 million compared to $47.4 million in the same quarter last year[9]. - Adjusted EBITDA for the quarter was $103,415 thousand, compared to $96,111 thousand in the same quarter of 2024, reflecting an increase of 7.4%[27]. - Non-GAAP adjusted net earnings for the quarter were $72,114 thousand, compared to $68,127 thousand in the same quarter of 2024, an increase of 4.4%[32]. - Earnings per share - diluted - Adjusted for the quarter was $0.46, up from $0.42 in the same quarter of 2024, indicating a growth of 9.5%[32]. Tax and Financial Position - The GAAP effective tax rate for the quarter was 25.2%, an increase from 18.6% in the same quarter of 2024[30]. - Total assets as of December 31, 2025, were $2,522,699 thousand, a decrease from $2,557,868 thousand as of June 30, 2025[38]. - Net earnings for the quarter ended December 31, 2025, were $38,009 thousand, an increase from $34,890 thousand in the same quarter of 2024, representing a growth of 6.4%[25]. - Net earnings for the six months ended December 31, 2025, increased to $76,194 million from $68,490 million in 2024, representing a growth of approximately 10.5%[40]. Cash Flow and Investments - Net cash provided by operating activities decreased to $109,996 million from $148,235 million, a decline of about 25.6%[40]. - Cash and cash equivalents at the end of the period were $172,879 million, compared to $177,549 million at the end of the previous period, reflecting a decrease of approximately 2.8%[40]. - The company reported a net cash used in investing activities of $5,316 million, a significant improvement from $26,716 million in the previous period[40]. - Cash dividends paid were $24,914 million, slightly down from $25,424 million, indicating a stable dividend policy[40]. - The effect of exchange rate changes on cash and cash equivalents resulted in a decrease of $797 million, highlighting currency impact on financial results[40]. Strategic Initiatives and Company Outlook - The company generated over $1.2 billion in net sales in fiscal 2025, with approximately 3,100 employees worldwide[14]. - The company celebrates its 50th anniversary in 2026, emphasizing its commitment to innovation and growth[4]. - Ongoing productivity and cost containment initiatives contributed to the improved operating margins across segments[10]. - The company’s non-GAAP financial measures aim to provide greater transparency and facilitate period-to-period comparisons of operational results[41]. - The adjusted operating margin excludes acquisition-related expenses and restructuring costs, which are not reflective of normal operating costs[44]. - The company’s investment in Spear Bio was recorded as a $15,000 million expense in the previous period, indicating strategic investment activities[40].

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights "I am pleased with the Bio-Techne team's continued execution in a stabilizing operating environment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "For the fourth consecutive quarter we delivered double-digit growth in our biggest end market, large pharma. That momentum, together with ...

Core Insights - Bio-Techne Corporation has launched Cultrex™ Synthetic Hydrogel, a synthetic extracellular matrix designed to enhance 3D stem cell and organoid research by reducing lot-to-lot variability and supporting reproducible workflows [1][3] Product Overview - Cultrex Synthetic Hydrogel supports 3D organoid models for applications such as drug screening, toxicology, and personalized medicine, minimizing reliance on animal-derived matrices and facilitating the use of new approach methodologies (NAMs) [2] - The hydrogel's controlled composition ensures consistency and traceability, aligning with regulatory requirements and enhancing preclinical research outcomes [3] Market Positioning - The launch of Cultrex Synthetic Hydrogel reflects the evolving needs of researchers transitioning from discovery to translational workflows, providing a scalable and reproducible option without compromising performance [4] - Bio-Techne's portfolio now includes a range of solutions for stem cell and organoid culture, offering flexibility to meet various experimental and regulatory needs [4] Company Background - Bio-Techne Corporation generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people globally, providing innovative tools and reagents for research and clinical diagnostics [6]

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Techne (TECH) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven st ...

Core Viewpoint - Bio-Techne Corporation (TECH) is expected to release its second-quarter fiscal 2026 results on February 4, with adjusted earnings per share (EPS) anticipated at 43 cents, reflecting a 2.4% increase from the previous year, while revenues are projected at $292 million, indicating a 1.7% decrease year-over-year [1][2]. Group 1: Earnings Performance - In the last reported quarter, Bio-Techne posted adjusted EPS of 42 cents, matching the Zacks Consensus Estimate, with the company beating earnings in three of the last four quarters and matching once, averaging a surprise of 6.58% [1]. - Estimates for earnings have remained constant at 43 cents over the past 30 days, indicating stability in expectations leading up to the announcement [3]. Group 2: Revenue Estimates - The Zacks Consensus Estimate for revenues is set at $292 million, which represents a decrease of 1.7% from the year-ago figure [2]. - The consensus estimate for the Spatial Biology segment's revenues is pegged at $81.6 million, down 3% from the previous year [15]. Group 3: Factors Influencing Performance - Ongoing macro uncertainties, including tariffs and potential NIH budget cuts, may add to customer uncertainty and temporarily slow growth momentum in the second quarter of fiscal 2026 [4]. - The timing related to cell therapy programs negatively impacted sales in the previous quarter, and this trend is expected to continue [5]. - The core portfolio of research-use-only proteomic agents, featuring over 6,000 proteins and 400,000 antibody types, is likely to support global customers in advancing therapeutics for precision diagnostics [6]. Group 4: Segment Developments - The protein analytical instrumentation business is expected to maintain strong momentum, with the ProteinSimple solution resuming double-digit growth [7]. - Demand for the next-generation high-throughput instrument, Leo, appears to be strong, contributing positively to quarterly results [8]. - Major developments include a licensing agreement with Monod Bio for exclusive rights to a subset of AI-designed bispecific binding proteins and a strategic distribution partnership with Sphere Bio for ultrasensitive immunoassays targeting Alzheimer's biomarkers [10]. Group 5: Challenges and Growth Areas - The Spatial Biology segment may face revenue declines due to the divestiture of the Exosome Diagnostics business, despite growth in the RNAscope product suite [12]. - The segment is likely to encounter headwinds from NIH funding uncertainties and a weaker biotech funding environment [13]. - The company has launched several new products and partnerships aimed at enhancing its offerings in spatial biology and diagnostics, which may contribute to top-line performance [14].

Core Insights - Bio-Techne Corporation has launched Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform, enhancing capabilities for neurodegenerative disease research [1][4]. Group 1: Product Launch and Features - The new assays provide step-change improvements in analytical sensitivity and reliable quantification of biomarkers such as NFL, GFAP, pTau 217, and Amyloid (aa1-42) [2][4]. - The Ella platform allows for femtogram-level detection, enabling precise quantification of low-abundance biomarkers that are often undetectable by conventional methods [4][5]. - The automated workflow of Ella reduces manual steps and variability, achieving an overall runtime of under three hours for assay results [4][7]. Group 2: Research Impact and Adoption - The assays facilitate the detection of subtle biological changes, accelerating insights into disease onset, progression, and treatment response [3][4]. - Ella has been cited in over 200 peer-reviewed publications focused on neurology, demonstrating its widespread adoption in translational and clinical research [3][5]. - Bio-Techne's immunoassay leadership is strengthened by combining ultrasensitive assays with automated instrumentation, improving reproducibility and data quality [5]. Group 3: Company Overview - Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people globally [6]. - The company provides innovative tools and bioactive reagents for research and clinical diagnostics, with a broad portfolio that drives breakthroughs in neuroscience research and precision medicine [6][5].

Company Overview - Bio-Techne is headquartered in Minneapolis and employs 3,100 colleagues across 34 global locations [2] - The company has developed a differentiated portfolio of protein-based core products over the last 50 years [2] Mission and Value Creation - The mission of Bio-Techne is to improve the quality of life by catalyzing advances in science and medicine, which drives the company's daily operations [2] - This mission is central to how the company creates value for both customers and shareholders [2]

Bio-Techne FY Conference Summary Company Overview - **Company Name**: Bio-Techne (NasdaqGS: TECH) - **Headquarters**: Minneapolis - **Employee Count**: 3,100 across 34 global locations - **Revenue**: $1.2 billion in 2025 - **Segments**: - Protein Sciences (73% of revenue) - Diagnostics and Spatial Biology (27% of revenue) [3][4] Core Business Insights - **Product Portfolio**: - 6,000 proteins and 400,000 antibodies - Focus on consumables (81% of revenue), instruments (9%), services (7%), and royalties (2%) [4] - **Revenue Breakdown**: - 41% from core reagents - 12% from diagnostic controls - 51% from biopharma, 20% from academia, 16% from diagnostics, 13% from distributors [5][6] Market Position and Strategy - **Total Addressable Market (TAM)**: $27 billion with significant growth potential [18][22] - **Growth Factors**: - Discovery of biological insights - Development of advanced therapeutics - Enablement of precision diagnostics [9][10] - **Key Applications**: - Cell therapies (7% of revenue) - Proteomic applications in drug development - Spatial interrogation [10][13] Financial Performance - **Revenue Growth**: 10% CAGR over the last five years despite market headwinds [19] - **Organic Revenue Growth**: 5% in fiscal 2025 [20] - **Profitability**: Targeting 35%-40% operating margins [23] Industry Trends - **Biotech Industry**: Experienced a decline in Q1 but showed signs of recovery with a 90% increase in funding in Q4 [24][25] - **Academic Sector**: Stabilizing with a shift in research focus from infectious diseases to chronic diseases [25][26] - **China Market**: Contributing 8% of revenue, showing potential for growth due to favorable government policies and funding [28][29] Cell Therapy Insights - **Growth in Cell Therapy**: Revenue reached $80 million, with $60 million from GMP proteins [30] - **Fast-Track Designation**: Two major customers received fast-track designation, potentially leading to significant future revenue [30][31] - **Clinical Trials**: 57% increase in cell therapy trials year-over-year [32] Diagnostics and Spatial Biology - **Market Size**: $5 billion for spatial biology, with 75% in translational and clinical markets [35] - **Innovations**: Introduction of RNAscope for RNA detection and COMET for multi-omic analysis [36][37] Future Outlook - **Growth Projections**: Anticipating low single-digit growth for fiscal 2026 due to current market conditions [41] - **Innovation Focus**: Continued investment in R&D (8% of revenues) and new product launches, including AI-designed proteins and ultra-sensitive immunoassays [38][39] - **M&A Strategy**: Plans to pursue acquisitions to enhance cell therapy and proteomic analytical capabilities [42] Conclusion - Bio-Techne is positioned for sustained growth through its differentiated product portfolio, strategic market focus, and commitment to innovation, despite facing short-term challenges in the biotech and academic sectors. The company aims to leverage its strengths to navigate market fluctuations and capitalize on emerging opportunities.

Company Overview - Bio-Techne has approximately 3,100 employees and is headquartered in Minneapolis, MN[12] - The company's FY2025 revenues reached approximately $1.2 billion[13] - Bio-Techne's market capitalization is approximately $10 billion[13] Revenue Breakdown - Consumables accounted for 81% of FY2025 revenues[15] - Instrument-specific consumables represented 12% of FY2025 revenues[15] - Services contributed 9% to FY2025 revenues[15] - Royalties made up 2% of FY2025 revenues[15] Market Segmentation & Geography - Pharma/Biotech represents 51% of the market[18] - Diagnostics accounts for 16% of the market[18] - Academia comprises 20% of the market[18] - Distributors make up 13% of the market[18] - Americas account for 58% of the geographic market[18] - EMEA represents 27% of the geographic market[18] - China accounts for 8% of the geographic market[18] - APAC makes up 7% of the geographic market[18] Financial Performance - Revenue increased from $738 million in 2020 to $1.215 billion in 2025, representing approximately 10% growth[44] - Adjusted operating income increased from $246 million in 2020 to $384 million in 2025, representing approximately 9% growth[44] Market Opportunity - The company is addressing a $27 billion market growing at a high-single-digit rate[48] - The market for Discovery of Novel Biological Insights is $14 billion with high-single-digit growth[40] - The market for Development and Manufacturing of Advanced Therapeutics is $5 billion with approximately 20% growth[40] - The market for Enablement of Precision Dx is $8 billion with mid-single-digit growth[40]